Ortec to Trade Under the Symbol ORTN.

Business Editors

BIOWIRE2K

NEW YORK--(BUSINESS WIRE)--June 24, 2003

Ortec International, Inc. announced today that as a result of the previously announced 1-for-10 reverse stock split of Ortec's common stock, which becomes effective at 5 p.m. Eastern Daylight Time on June 24, 2003, Nasdaq has assigned Ortec a new trading symbol Trading symbol

See: Ticker symbol .

Ortec's previous symbol, ORTC ORTC Old Republic Title Company
ORTC Operational Readiness Training Complex , will be changed to ORTN ORTN Office de Radiodiffusion et Télévision du Niger (French) , effective June 25, 2003.

COPYRIGHT 2003 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Geographic Code:	1USA
Date:	Jun 24, 2003
Words:	66
Previous Article:	The Complete First Season of the WB's High-Flying Television Series ``Smallville'' Muscles Its Way onto DVD September 23 from Warner Home Video.
Next Article:	Witness Systems and its Customers Receive Top Industry Honors.
Topics:	Biological products industry

Related Articles
ORTEC SUCCESSFULY DEFENDS EUROPEAN PATENT ON ORCEL.
Ortec Announces Completion of Patient Enrollment for its Phase III Venous Leg Ulcer Pivotal Trial; PMA Filing for OrCel on Track for 4Q 2003.
Clinical Results of Ortec's OrCel in Treating Foot Ulcers Featured in Peer Reviewed Journal 'Wounds'.
Ortec Signs Sales and Marketing Agreement with Teva.
Ortec Issued Patent Covering OrCel's Cryopreservation Process; Patent is Fifth Issued to Ortec.
Ortec Provides Update of PMA Status and Auditor Selection.
Ortec Provides FDA Update.
Ortec to Participate in Tissue Engineering Skin Roundtable At SAWC Annual Meeting; Cambrex and Ortec to Exhibit OrCel at SAWC.
Ortec and Center for Tissue Engineering at University of California at Berkeley to Collaborate on Cardiovascular Tissue Regeneration.
Ortec Set to Initiate 60 Patient Confirmatory Trial For Venous Leg Ulcer Approval; Final Version of Study Protocol and Clinical Design Submitted to...